Clinical Trial Update: Bioequivalence Study of Fixed-dose Combinations and Coadministered Individual Tablets of Saxagliptin/Metformin-Brazil [Phase 1]

View source ↗

Summary

Phase 1 bioequivalence study in Brazil comparing fixed-dose combination Saxagliptin/Metformin to coadministered tablets in type 2 diabetes; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Saxagliptin/Metformin fixed-dose combination (saxagliptin and metformin)

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes Mellitus | Phase 1 | Status: COMPLETED | Results posted: 2013-08-19